Background: Malignant tumours of the salivary glands (MSGT) are rare and pleomorphic entities. Patients with advanced disease may benefit from targeted therapy; however, specific targets for optimising and personalising treatments are yet to be identified.
introduction
Malignant salivary gland tumours (MSGT) are rare, representing ∼6% of all head and neck neoplasms. The latest World Health Organisation (WHO) classification individualises 24 epithelial subtypes, making each entity even rarer. Five subtypes represent 80% of all tumours [mucoepidermoid carcinoma (MEC), adenoid cystic carcinoma (AdCC), acinic cell carcinoma (ACC), adenocarcinoma not otherwise specified (NOS) and carcinoma ex-pleomorphic adenoma]. Histological aspects vary widely between subtypes, and a simpler classification based on prognosis was proposed by Regezi et al. [1] (supplementary Table S1 , available at Annals of Oncology online).
Curative treatment relies on surgery, which can be complemented by radiotherapy. However, tumours are often slow growing and are discovered at an advanced, non-surgical stage. Management of locally advanced or metastatic tumours is difficult as conventional chemotherapies have poor efficacy. Targeted therapies may offer significant benefits for these patients; however, to date, there are no guidelines or tools for selecting candidate patients. Targeted therapies include older molecules such as anti-estrogens or androgens, more recent molecules such as anti-HER2/EGFR/mTOR agents, and molecules in early clinical testing such as a PI3K inhibitor and an anti-MUC1 vaccine. Reports on the expression of targeted molecules are rare, highly heterogeneous, and sometimes totally contradictory, mainly because of small patient groups and the use of different antibodies.
The aim of this study was to systematically assess in one of the largest retrospective cohorts of epithelial MSGT the expression and prognostic value of treatment-relevant targets as well as the mutational status of genes involved in anti-EGFR therapy responses, and to perform a large screen for mutations in key oncogenic players to unveil new pathways to target.
patients and methods patients
The study was approved by the G. Pompidou European Hospital ethics committee. Patients were selected from pathology databases of three Paris hospitals using all epithelial MSGT subtypes as search terms and a surgery date between 1991 and 2010. Of the 132 patient files retrieved, 123 were included (supplementary Figure S1 , available at Annals of Oncology online). Demographic, clinical and pathology data were collected from surgical and pathology records. Tumours were analysed by subtypes defined by the WHO classification and grouped into low-, intermediate-and high-grade tumours according to the classification proposed by Regezi et al. [1] .
immunochemistry Tumour specimens were fixed in formalin and paraffin embedded. Details of primary antibodies, staining procedures and positive controls are listed in supplementary Table S2 , available at Annals of Oncology online, and samples of positive staining are shown in supplementary Figure S2 , available at Annals of Oncology online. Two pathologists independently interpreted the staining, blinded to the clinical outcome. Discordant cases were discussed to reach an agreement. The percentage of positive cells for Ki67, androgen/ estrogen/progesterone receptors (nuclear staining), C-KIT (membrane and cytoplasmic) and mTOR (cytoplasmic) was recorded. A semi-quantitative analysis based on mammary pathology was used for HER2 and EGFR. MUC1 expression was assessed by the percentage of stained cells and staining intensity (weak/moderate/strong).
DNA extraction and mutational screen DNA was isolated from microdissected tumours using the QIAamp DNA Mini Kit (Qiagen, Courtaboeuf, France). DNA damaging fixative or insufficient material prevented the analysis of 16 patients, giving 107 patients with good-quality DNA. KRAS codon 12 and 13 mutations, BRAF p.V600E and EGFR p.L858R were screened by allelic discrimination. For BRAF and EGFR probes, sensitivity was increased by addition of a peptide nucleic acid blocker. KRAS codon 61 and HRAS codons 12-13-61 mutations were assessed by direct sequencing. Detection of deletions or insertions in exon 19 of EGFR and 20 of EGFR and HER2 was carried out by fragment analysis. All primer sequences are available on request. A high throughput mutational screen was carried out on 87 samples with sufficient DNA using a custom panel on the Sequenom® automate (supplementary Table S3 , available at Annals of Oncology online).
statistical analysis
Data were analysed using the STATA software version 11 (Stata, Inc., College Station, TX, USA). Tests were two-tailed and P-values <0.05 were considered. Overall survival was measured from surgery to the last follow-up or death. Event-free survival was measured from surgery to the last followup or local recurrence or metastasis. Overall and event-free survival were estimated by the Kaplan-Meier method. Factors potentially influencing progression-free and overall survival were tested by comparing survival curves with the log-rank test. A stepwise Cox's proportional hazards model was used to simultaneously account for all potential prognostic factors over time. Variables emerging from univariate models with a P-value of <0.15 were included in the final multivariate model. Hazard ratios and two-sided 95% confidence interval (95% CI) were estimated. results population, tumour characteristics and treatments Sixty-two women (50.4%) and 61 men with a mean age of 52 (±18) years were included. Tumour characteristics are summarised in Table 1 . Data on adjuvant treatment following surgery were available for 99 patients (80%); 51 had no adjuvant therapy, 4 received chemotherapy alone, 18 had radiotherapy alone (typically 66 Gy) and 26 received chemotherapy followed by radiotherapy. Chemotherapy regimens, when available, were mostly based on platinum salts (carboplatin or cisplatin in 14 and 3 patients, respectively), sometime associated with 5-fluorouracil (7 patients). Taxol-based chemotherapies were rare (3 patients). Eight personalised therapy targets were tested for expression levels ( Table 2) . Expression was relatively homogeneous for all markers tested. C-KIT was the most frequently expressed marker (55 of 112, 49.1% overall). Only cases showing a strong EGFR and HER2 expression (score 3+ using mammary pathology criteria) were considered positive. If cases with a score of 2+ were also considered positive, then EGFR was the most expressed marker (61 of 109, 56% of cases). Marker expression was rarely restricted to a tumour subtype, but clear trends were observed. Androgen receptor and HER2 expression were strong and common in salivary duct carcinomas (SDC).
EGFR expression was present in almost half of MEC and adenocarcinoma NOS. C-KIT expression was seen in virtually all cases of AdCC and in over three-quarters of epithelial myoepithelial carcinomas. MUC1 (moderate and strong expression) and phospho-mTOR were mostly positive in adenocarcinoma NOS and ACC, respectively. The progesterone receptor was never expressed and estrogen receptors rarely. The proliferation index, MIB1/Ki67, was over 20% in a quarter of cases (cut-off chosen from the literature [2] ). SDC and adenocarcinoma NOS had the highest mean proliferation index. MIB1/Ki67 was associated with a tumour grade [odds ratio (OR) 4.9 (95% CI 1.8-13.7)].
tumour and patient characteristics associated with progression-free and overall survival Univariate analyses are summarised in Tables 3 and 4 . Tumour grade showed the strongest association with progression-free and overall survival. Lymph node metastasis was associated with overall survival. R1 surgery status was associated with faster recurrence, but had no impact on overall survival. Ki67 was the only molecular marker associated with progression-free and overall survival. Chemotherapy followed by radiochemotherapy, but not chemotherapy or radiotherapy alone, was associated with both outcomes. In multivariate analyses, tumour grade was independently associated with both outcomes, while age >50 years and low proliferation index were only associated with shorter overall survival.
mutations within the EGFR pathway and other key oncogenes
Results of both mutational screens were concordant (supplementary Table S3 , available at Annals of Oncology online). Twenty-four alterations were identified in 22 samples. No classical activating mutations or insertion/deletions within exons 19 and 20 of EGFR were found. One tumour had an insertion of 3AA in HER2 exon 20 without overexpression (score 1+). Exploration of downstream KRAS/BRAF/MEK/ERK showed no mutation in codons 12/13 of KRAS, but one myoepithelial carcinoma had an activating KRAS mutation at codon 61 (c.182 A > T, p.Q61L). Two other tumours (carcinoma ex-pleomorphic adenoma and MEC) had a rare KRAS mutation (c.175G > A, pA59T), whose significance is not yet clear. No classical activating mutation (V600E) was found in BRAF, but an AdCC had a c.1781 A > G, pD594G mutation.
Exploration of downstream PI3K/Akt/mTOR showed no PTEN or Akt2 mutations; however, five samples had mutated Table 2 . 
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PI3K (two activating mutations in exon 1, two in exon 9 and one in exon 20) and a TP53 gain-of-function mutation known to activate HRAS and the EGFR/PI3K was present in two cases (c.818G > A, p.R175H) [3] . Activating HRAS mutations involving codon 61 (c.182 A > T, p.Q61L, one case and c.182 A > G, p.Q61R, six cases) were present in 7% (7 of 107) of tumours. Subtype analysis revealed that, in tumours with a myoepithelial component, the mutation rate reached 33% (3 of 9) (one of three myoepithelial carcinomas and two of six epithelial myoepithelial carcinomas). In one myoepithelial carcinoma, the HRAS p.Q61R mutation was either homozygous or associated with loss of heterozygosity. Activating mutations of NRAS were present in two cases (codons 12 and 13). Further downstream, rare mutations within MAP2K4&7 were found [MAP2K4 p.S251N (c.752G > A) in a MEC and MAP2K7 p.R162H (c.485G > A) in an adenocarcinoma NOS]. Two tumours had more than one mutation; a carcinoma ex-pleomorphic adenoma had KRAS (c.175G > A, pA59T) and PI3K (c.1624G > A, p.E542K) mutations, while an AdCC had NRAS (c.34G > C, p.G12R) and a PI3K (c.1633G > A, p.E545K) mutations.
The presence of an EGFR pathway mutation was not associated with progression-free survival [hazard ratio (HR) = 1.28 (95% CI 0.48-3.43), P = 0.62], but a trend could be seen with overall survival [HR 2.62 (95% CI 0.82-8.4), P = 0.11] in univariate analyses.
No tumours had common oncogenic mutations in CTNNB1/ PDGFRα/SMAD4/FBXW7/cMET/STK11.
In summary, 18 of the 107 (16.8%) tumours had at least one genetic alteration that was exclusive for KRAS, BRAF, HRAS, NRAS and PI3K.
discussion
We present a comprehensive expression and mutational analysis of treatment-relevant targets in the largest study in MSGT to date. This retrospective study evaluated 123 patients treated in three hospitals over a 19-year period and included rare, often aggressive tumour subtypes for which no data have been published. The expression of targets is in accordance with the literature, but none was related to prognosis except Ki-67. EGFR overexpression and the absence of C-KIT have been reported as poor prognosis biomarkers [4] ; however, this discrepancy may be explained by the population. Over one-third of the patients were included in the last 3 years, which may have undermined the prognostic analysis, especially with slow-growing tumours.
Only molecular alterations related to targeted therapies were tested in this study. Although some translocations are frequent in MEC t(11;19)(CRYC1-MAML2) or AdCCs t(6;9)(MYB-NFIB) and have a prognostic impact, they are not yet targeted by specific inhibitors [5, 6] .
Progesterone receptors were never expressed and estrogen receptors exceptionally as published elsewhere [7] . These results suggest that tamoxifen or aromatase inhibitor-based therapies are unlikely to have an effect.
Androgen receptor expression is also globally infrequent, but a subtype analysis revealed that 'excretory type tumours' such as SDC and adenocarcinoma NOS did express the receptor in 66.7% (2 of 3) and 33.3% (4 of 12) of cases, respectively, in accordance with expression levels reported elsewhere [8] . Japser et al. recently reported the treatment of 10 patients with locally advanced or metastatic SDC using a non-steroidal antiandrogen (bicalutamide). Half the patients showed regression or stabilisation and the median progression-free survival of 12 months was higher than that previously reported with conventional chemotherapy [9] . Targeting HER2 may also be effective in these tumours. Of the three SDC cases tested, one showed strong HER2 expression (3+) and one a potentially activating insertion of three amino acids in exon 20 of HER2. Although we did not test for HER2 gene amplification, several studies confirmed that, in MSGT, as in mammary carcinoma, a 3+ score in immunochemistry is frequently associated with HER2 amplification [10] [11] [12] . These results together with reports of selected SDC cases with HER2 amplification successfully treated with traztuzumab are encouraging [13] . HER2 was also overexpressed in 2 of 12 adenocarcinoma NOS cases and may represent a treatment option.
C-KIT was overexpressed in most AdCC (34 of 37, 91.9%). In contrast to outcomes with gastrointestinal stromal tumours, tyrosine kinase inhibitors such as imatinib are not active in AdCCs, probably because most tumours harbour a wild-type C-KIT, suggesting that this pathway is not driving tumourigenesis [14, 15] . C-KIT was also widely expressed in epithelial-myoepithelial carcinoma and to a lesser extent in myoepithelial carcinoma (5 of 6, 83.3% and 1 of 6, 16.7%, respectively). Since it is not known whether these tumours have a wild-type or activated C-KIT protein, it may be feasible to treat with imatinib depending on the C-KIT mutational status.
EGFR was the most widely expressed marker if the score 2+ and 3+ were considered positive. A strong overexpression (score 3+ using HER2 criteria) was found in almost half of MEC and carcinoma ex-pleomorphic adenoma (10 of 22, 45.5% and 5 of 12, 41.7%, respectively). The meaning of this overexpression on tumourigenesis is not clear. In other tumour types, EGFR overexpression did not correlate with the response to EGFRblocking antibodies such as cetuximab [16] . Nevertheless, several studies using cetuximab or lapatinib (a dual EGFR/ HER2 inhibitor) were promising [10, 17] . Our mutational screen showed several tumours harbouring activating mutations of KRAS, NRAS, HRAS and MAPK on the one hand, and PI3K as well as PI3K activating mutation of TP53 on the other hand. Mutations within the EGFR pathway were weakly associated with overall survival (HR 2.62, 95% CI 0.82-8.4, P = 0.11) in univariate analysis; however, tumour types were heterogeneous and subgroups too small to perform meaningful statistical analyses. Recent reports from Ettl et al. in a large cohort of MGST demonstrated that 15% of cases had a chromosome 7 polysomy (containing the EGFR gene) and fewer cases had an EGFR amplification. These molecular alterations were associated with a worse outcome [11, 12] . Taken together, these data suggest a role of the EGFR pathway in MSGT growth.
No activating alterations of EGFR or BRAF were found suggesting low efficacy with tyrosine kinase inhibitors. Rare tumours (2 of 107) had non-classical KRAS or BRAF mutations, implying that cetuximab could be used (without pre-therapeutic screening). mTOR inhibitors such as everolimus and future PI3K inhibitors should be tested, especially in ACC in which mTOR is often activated (5 of 13, 38.5%). In addition, two ACC original articles Annals of Oncology cases had molecular alterations in this pathway, one harbouring a classical activating mutation in exon 20 of PI3K ( p.H1047R) and the other a TP53 mutation ( p.R175H), which activates the EGFR/PI3K pathway [3, 18] . No mutations in PTEN were found, but Ettl et al. reported that about 20% of MSGT had a deletion in PTEN [11] . These tumours had a worse prognosis and may be responsive to dual mTOR/PI3K inhibitors.
The most frequently mutated oncogene was HRAS (7% overall, 7 of 107) especially in myoepithelial rich tumour subtypes (3 of 9). This novel tumourigenic pathway in MSGT is important in other tumour types such as papillary urothelial tumours [19] . The impact of HRAS activation on cetuximab response is not clearly established, but some reports indicate diminished activity in mutated cases prompting systematic testing of HRAS in these tumours. Two cases had two concomitant mutations within the EGFR pathway (KRAS/PI3K and NRAS/PI3K). Whether these two mutations are present in all cells or represent two tumour clones cannot be distinguished with the technique used.
In conclusion, this report presents the largest MSGT series with a systematic analysis of the expression of treatmentrelevant targets together with a mutational analysis of genes either driving tumourigenesis or important for response to such therapies. Several tumour subtypes frequently overexpressed some targets of directed therapies often associated with mutations or activation of downstream components confirming the importance of the underlying pathway and suggesting therapy leads such as traztuzumab or androgen inhibitors in SDC or anti-mTOR in ACC. Frequent overexpression of EGFR and activating mutations of PI3K/NRAS/HRAS/MAPK in some subtypes are strong arguments to target this pathway. To this end, the absence of mutations in EGFR/KRAS/BRAF favours antibody-based anti-EGFR therapy rather than tyrosine kinase inhibitors directed against EGFR or BRAF. The activating mutations are individually rare and not restricted to a subtype prompting for individual molecular testing. The availability of next-generation sequencing will soon allow rapid testing of the entire pathway to select optimal targeted therapy. Finally, in some specific subtypes, the high frequency of HRAS mutation may suggest the involvement of the Wnt/βcatenin pathway by analogy with urothelial tumours.
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